hh.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium
Axiogenesis AG, 50931 Cologne, Germany.
Institute of Physiology I, University of Bonn, 53105 Bonn, Germany.
Department of Cardiac Surgery, University of Bonn, 53105 Bonn, Germany.
Institute of Physiology I, University of Bonn, 53105 Bonn, Germany.
Show others and affiliations
2006 (English)In: Journal of Experimental Medicine, ISSN 0022-1007, E-ISSN 1540-9538, Vol. 203, no 10, 2315-2327 p.Article in journal (Refereed) Published
Abstract [en]

Cellular cardiomyoplasty is an attractive option for the treatment of severe heart failure. It is, however, still unclear and controversial which is the most promising cell source. Therefore, we investigated and examined the fate and functional impact of bone marrow (BM) cells and embryonic stem cell (ES cell)-derived cardiomyocytes after transplantation into the infarcted mouse heart. This proved particularly challenging for the ES cells, as their enrichment into cardiomyocytes and their long-term engraftment and tumorigenicity are still poorly understood. We generated transgenic ES cells expressing puromycin resistance and enhanced green fluorescent protein cassettes under control of a cardiac-specific promoter. Puromycin selection resulted in a highly purified (>99%) cardiomyocyte population, and the yield of cardiomyocytes increased 6-10-fold because of induction of proliferation on purification. Long-term engraftment (4-5 months) was observed when co-transplanting selected ES cell-derived cardiomyocytes and fibroblasts into the injured heart of syngeneic mice, and no teratoma formation was found (n = 60). Although transplantation of ES cell-derived cardiomyocytes improved heart function, BM cells had no positive effects. Furthermore, no contribution of BM cells to cardiac, endothelial, or smooth muscle neogenesis was detected. Hence, our results demonstrate that ES-based cell therapy is a promising approach for the treatment of impaired myocardial function and provides better results than BM-derived cells.

Place, publisher, year, edition, pages
New York, USA: Rockefeller University Press, 2006. Vol. 203, no 10, 2315-2327 p.
Keyword [en]
Animals, Bone Marrow Transplantation, DNA Primers, Electrophysiology, Embryonic Stem Cells, Green Fluorescent Proteins, Immunohistochemistry, Mice, Myocardial Contraction, Myocardial Infarction, Myocytes, Cardiac, Puromycin, Reverse Transcriptase Polymerase Chain Reaction
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:hh:diva-15174DOI: 10.1084/jem.20061469PubMedID: 16954371Scopus ID: 2-s2.0-33749367585OAI: oai:DiVA.org:hh-15174DiVA: diva2:419612
Available from: 2011-05-27 Created: 2011-05-27 Last updated: 2015-09-21Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Nygren, Jens Martin
In the same journal
Journal of Experimental Medicine
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 102 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf